Efficacy and Safety of Lenalidomide, PD-1 Monoclonal Antibodies Combined with Orelabrutinib in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Multicenter, Open-Label, Single-Arm, Phase II Study

被引：0
|
作者：
Wang, Lingling [1 ]
Huang, Yongfen [1 ]
Chen, Hui [1 ]
Xu, Hao [1 ]
Cheng, Yuexin [1 ]
Miao, Yuqing [1 ]
机构：
[1] Xuzhou Med Univ, Peoples Hosp Yancheng 1, Yancheng Clin Coll, Dept Hematol, Yancheng, Peoples R China
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-198309
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6488 / 6489
页数：2
相关论文
共 50 条
  • [31] Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study
    Salles, Gilles
    Duell, Johannes
    Gonzalez Barca, Eva
    Tournilhac, Olivier
    Jurczak, Wojciech
    Liberati, Anna Marina
    Nagy, Zsolt
    Obr, Ales
    Gaidano, Gianluca
    Andre, Marc
    Kalakonda, Nagesh
    Dreyling, Martin
    Weirather, Johannes
    Dirnberger-Hertweck, Maren
    Ambarkhane, Sumeet
    Fingerle-Rowson, Gunter
    Maddocks, Kami
    LANCET ONCOLOGY, 2020, 21 (07): : 978 - 988
  • [32] A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma; Prelininary results.
    Richardson, P
    Jagannath, S
    Hussein, M
    Berenson, J
    Singhal, S
    Irwin, D
    Williams, SF
    Bensinger, W
    Badros, AZ
    Vescio, R
    Kenvin, L
    Yu, ZN
    Olesnyckyj, M
    Faleck, H
    Zeldis, J
    Knight, R
    Anderson, KC
    BLOOD, 2005, 106 (11) : 449A - 449A
  • [33] Polatuzumab vedotin plus rituximab and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study
    Abrisqueta, Pau
    Gonzalez-Barca, Eva
    Panizo, Carlos
    Perez, Jose Maria Arguinano
    Miall, Fiona
    Bastos-Oreiro, Mariana
    Triguero, Ana
    Banerjee, Lalita
    Mcmillan, Andrew
    Seymour, Erlene
    Hirata, Jamie
    de Guzman, Jayson
    Sharma, Sunil
    Jin, Hyun Yong
    Musick, Lisa
    Diefenbach, Catherine
    LANCET HAEMATOLOGY, 2024, 11 (02): : e136 - e146
  • [34] An Open-Label Phase II Study of Buparlisib (BKM120) in Patients with Relapsed and Refractory Diffuse Large B-Cell Lymphoma, Mantle Cell Lymphoma or Follicular Lymphoma
    Younes, Anas
    Salles, Gilles
    Bociek, R. Gregory
    Martinelli, Giovanni
    Caballero, Dolores
    Gonzalez Barca, Eva
    Mukherjee, Nabanita
    Williams, Lisa
    Herbst, Fabian
    Tavorath, Ranjana
    Kim, Won Seog
    BLOOD, 2014, 124 (21)
  • [35] Lenalidomide maintenance in patients with relapsed diffuse large B-cell lymphoma who are not eligible for autologous stem cell transplantation: an open label, single-arm, multicentre phase 2 trial
    Ferreri, Andres J. M.
    Sassone, Marianna
    Zaja, Francesco
    Re, Alessandro
    Spina, Michele
    Di Rocco, Alice
    Fabbri, Alberto
    Stelitano, Caterina
    Frezzato, Maurizio
    Rusconi, Chiara
    Zambello, Renato
    Couto, Suzana
    Ren, Yan
    Arcari, Annalisa
    Bertoldero, Giovanni
    Nonis, Alessandro
    Scarfo, Lydia
    Calimeri, Teresa
    Cecchetti, Caterina
    Chiozzotto, Marianna
    Govi, Silvia
    Ponzoni, Maurilio
    LANCET HAEMATOLOGY, 2017, 4 (03): : E137 - E146
  • [36] PI3Kδ inhibitor linperlisib combined with gemcitabine and oxaliplatin for relapsed or refractory diffuse large B-cell lymphoma: a multicenter, single-arm phase Ib/II trial
    Sun, Peng
    Cen, Hong
    Yang, Haiyan
    Huang, Rui
    Cai, Zhen
    Gu, Xuekui
    Bao, Hanying
    Xu, Zusheng
    Xu, Zuhong
    Li, Zhi-Ming
    CANCER CELL INTERNATIONAL, 2025, 25 (01)
  • [37] Pan-cancer efficacy and safety of anlotinib plus PD-1 inhibitor in refractory solid tumor: A single-arm, open-label, phase II trial
    Qin, Bao-Dong
    Jiao, Xiao-Dong
    Wang, Zhan
    Liu, Ke
    Wu, Ying
    Ling, Yan
    Chen, Shi-Qi
    Zhong, Xue
    Duan, Xiao-Peng
    Qin, Wen-Xing
    Xue, Lei
    Guo, Zhen-Hong
    Zang, Yuan-Sheng
    INTERNATIONAL JOURNAL OF CANCER, 2023, 153 (04) : 815 - 825
  • [38] Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study
    Ansell, Stephen M.
    Minnema, Monique C.
    Johnson, Peter
    Timmerman, John M.
    Armand, Philippe
    Shipp, Margaret A.
    Rodig, Scott J.
    Ligon, Azra H.
    Roemer, Margaretha G. M.
    Reddy, Nishitha
    Cohen, Jonathon B.
    Assouline, Sarit
    Poon, Michelle
    Sharma, Manish
    Kato, Kazunobu
    Samakoglu, Selda
    Sumbul, Anne
    Grigg, Andrew
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (06) : 481 - +
  • [39] Preliminary Safety and Efficacy of Zanubrutinib in Combination with Lenalidomide in Patients with Relapsed/ Refractory Diffuse Large B-Cell Lymphoma
    Zhang, Huilai
    Zhou, Keshu
    Cheng, Ying
    Zhang, Liling
    Yang, Haiyan
    Zou, Liqun
    Cao, Junning
    Huang, Huiqiang
    Guo, Ye
    Wang, Zhao
    Huang, Sha
    Liang, Zhiyu
    Yao, Hui
    Guo, Haiyi
    Fang, Yiqian
    Zhu, Hongjie
    BLOOD, 2022, 140 : 3750 - 3751
  • [40] A Phase II, Multicenter, Single-Arm, Open-Label Study of Parsaclisib, a PI3Kd Inhibitor, in Relapsed or Refractory Follicular Lymphoma in China
    Zheng, Zhong
    Zhang, Huilai
    Wang, Jingwen
    Zhou, Keshu
    Zhang, Li
    Zhou, Hui
    Zhang, Qingyuan
    Zhao, Weili
    BLOOD, 2021, 138
12345